How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices

Abstract

Objective:

The aim of this study was to assess the quality of TURBT (transurethral resection of bladder tumor) using surrogate parameters and evaluate adherence to the guidelines regarding the management of bladder tumors.

Materials and methods:

A clinical audit of all new diagnosis of bladder cancer was undertaken from January 2016 to January 2017. A total of 101 new bladder cancer cases were included. Surrogates of TURBT quality including presence of detrusor in the specimen, rate of re-TUR, presence of carcinoma in situ, and 3-month recurrence rates were analyzed. Adherence to guidelines regarding management of non-muscle invasive bladder cancer including time to re-TUR and utilization of single instillation chemotherapy was evaluated.

Results:

Absence of detrusor muscle in the specimen of the initial TURBT was noted in 22.8% of the cases. The chance of including muscle in the specimen was almost four-fold for tumors larger than 3 cm. A single instillation of intravesical chemotherapy following TURBT was administered in only 40% of eligible patients; 54.3% of patients had a re-TUR, the majority (61.3%) for high-grade non-muscle invasive bladder cancer on initial TURBT. Re-TUR was done on average 10 weeks after initial TURBT. The 3-month recurrence rate was 36.0% with larger tumors (>3 cm) being more prone to early recurrences. Early recurrences were not affected by intravesical instillations with bacillus Calmette–Guérin or mitomycin C although there was a positive association between the presence of carcinoma in situ on initial resection and early recurrences.

Discussion and conclusion:

One in two patients will have a re-TUR, and approximately one in two patients will have tumor on re-TUR. Single immediate chemotherapy instillations after TURBT are underutilized. The presence of carcinoma in situ on initial TURBT and tumor size were predictors of early recurrences.

Keywords

Bladder cancer TURBT guidelines re-TUR recurrences

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

Cancer statistics. CA Cancer J Clin 2019; 69(1): 7–34.

Nice.org.uk. Bladder cancer: diagnosis and management. Guidance: NICE, 2015, https://www.nice.org.uk/guidance/ng2/resources/bladder-cancer-diagnosis-and-management-pdf-51036766405 (accessed 8 September 2019).

Babjuk

Böhle

Burger

, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017; 71(3): 447–461.

Chang

Boorjian

Chou

, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016; 196(4): 1021–1029.

Gendy

Delprado

Brenner

, et al. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. BJU Int 2016; 117: 54–59.

Brausi

Gavioli

Peracchia

, et al. Dedicated teaching programs can improve the quality of tur of non-muscle-invasive bladder tumours (NMIBT): experience of a single institution. Eur Urol Suppl 2018; 7(3): 180.

Yuk

Kim

Jeong

, et al. Differences in pathologic results of repeat transurethral resection of bladder tumor (TURBT) according to institution performing the initial TURBT: comparative analyses between referred and nonreferred group. Biomed Res Int 2018; 2018: 9432606.

Rolevich

Minich

Nabebina

, et al. Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer. Cent European J Urol 2016; 69(2): 170–177.

Hurle

Peschechera

Buffi

, et al. Impact of a teaching program on outcome quality of white light transurethral resection for bladder tumor: a cohort study. J Solid Tumors 2016; 6(2): 56–61.

10.

Mariappan

Finney

Head

, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012; 109(11): 1666–1673.

11.

Shoshany

Mano

Margel

, et al. Presence of detrusor muscle in bladder tumor specimens—predictors and effect on outcome as a measure of resection quality. Urol Oncol 2014; 32(1): 40.e17–40.e22.

12.

Kassouf

Aprikian

Black

, et al. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J 2016; 10(1–2): E46–E80.

13.

Sylvester

Oosterlinck

Holmang

, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 2016; 69(2): 231–244.

14.

Zamboni

Baumeister

Mattei

, et al. Single postoperative instillation for non-muscle invasive bladder cancer: are there still any indication. Trans Androl Urol 2019; 8(1): 76–84.

15.

Palou-Redorta

Roupret

Gallagher

, et al. The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries. World J Urol 2014; 32(2): 525–530.

16.

Naselli

Hurle

Paparella

, et al. Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 2018; 4(4): 558–567.

17.

Gontero

Sylvester

Pisano

, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int 2016; 118(1): 44–52.

18.

Soria

Marra

D’Andrea

, et al. The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. Transl Androl Urol 2019; 8(1): 46–53.

19.

Skafianos

Kim

Hakimi

, et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette–Guerin. Eur Urol 2015; 67: 815.

20.

Bryan

Collins

Daykin

, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann Royal Coll Surg Engl 2010; 92(6): 519–524.

21.

Guney

Canogullari

, et al. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year. Urol Int 2008; 80(2): 124–128.

22.

Koie

Ohyama

Hosogoe

, et al. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Int Urol Nephrol 2015; 47(9): 1509–1514.

23.

Liu

Hou

Zhang

, et al. The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBT) in Chinese population. PLoS ONE 2015; 10(4): e0123617.

24.

Sylvester

Brausi

Kirkels

, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette–Guérin, and bacillus Calmette–Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57(5): 766–773.

25.

Palou

Rodríguez-Rubio

Millán

, et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology 2009; 73(6): 1313–1317.

26.

Hayakawa

Kikuchi

Mikami

, et al. The clinical impact of the classification of carcinoma in situ on tumor recurrence and their clinical course in patients with bladder tumor. Japan J Clin Oncol 2011; 41(3): 424–429.

27.

Lamm

DL.

Carcinoma in situ. Urol Clin North Am 1992; 19(3): 499–508.

28.

Zurkirchen

Sulser

Gaspert

, et al. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists. Urol Int 2004; 72(2): 99–102.